Meanwhile, co-targeting the tumor with modified CAR T cells and CXCR4/CXCL12 inhibitors such as AMD3100 and NOX-A12 resulted in higher CAR T cell accumulation in the tumor microenvironment and superior anticancer activity compared to adoptive T cell therapy alone [82]. Here, CXCR4 is linked to neoplasm.